PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22551975-1 2012 Suberoylanilide hydroxamic acid (SAHA) has been approved for the treatment of cutaneous T-cell lymphoma (CTCL), but its mode of action remained largely elusive. Vorinostat 0-31 TSPY like 2 Homo sapiens 105-109 24850846-10 2014 Treatment of CTCL cells in vitro with vorinostat or romidepsin histone deacetylase inhibitors resulted in a significant dose-dependent upregulation of mRNA but not protein. Vorinostat 38-48 TSPY like 2 Homo sapiens 13-17 23820962-3 2013 Vorinostat is presently indicated for the treatment of patients with advanced cutaneous T cell lymphoma (CTCL). Vorinostat 0-10 TSPY like 2 Homo sapiens 105-109 23820962-12 2013 CONCLUSIONS: Vorinostat"s favorable clinical pharmacology and drug interaction profile aid in the ease of administration of vorinostat for the treatment of advanced CTCL and will be beneficial in continued assessment for other oncologic indications. Vorinostat 13-23 TSPY like 2 Homo sapiens 165-169 23820962-12 2013 CONCLUSIONS: Vorinostat"s favorable clinical pharmacology and drug interaction profile aid in the ease of administration of vorinostat for the treatment of advanced CTCL and will be beneficial in continued assessment for other oncologic indications. Vorinostat 124-134 TSPY like 2 Homo sapiens 165-169 23141799-6 2012 Interest is increasing in HDI-based therapies and so far, two HDIs, vorinostat (SAHA) and romidepsin (FK228), have been approved for treating cutaneous T-cell lymphoma (CTCL). Vorinostat 68-78 TSPY like 2 Homo sapiens 169-173 23141799-6 2012 Interest is increasing in HDI-based therapies and so far, two HDIs, vorinostat (SAHA) and romidepsin (FK228), have been approved for treating cutaneous T-cell lymphoma (CTCL). Vorinostat 80-84 TSPY like 2 Homo sapiens 169-173 22551975-7 2012 Comparable proapoptotic responses to SAHA and to the combination with TRAIL were seen in ex vivo tumor T cells of CTCL patients. Vorinostat 37-41 TSPY like 2 Homo sapiens 114-118 22551975-8 2012 Thus, activation of extrinsic apoptosis pathways, related to c-FLIP downregulation and enhanced TRAIL signaling, appeared as characteristic for CTCL cell responsiveness to SAHA. Vorinostat 172-176 TSPY like 2 Homo sapiens 144-148 22506596-1 2012 A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Vorinostat 152-162 TSPY like 2 Homo sapiens 239-243 22506596-7 2012 The safety and PK profiles of vorinostat in Japanese patients with CTCL did not appear to differ from those previously observed in non-Japanese and Japanese patients with advanced solid tumors. Vorinostat 30-40 TSPY like 2 Homo sapiens 67-71 22551975-1 2012 Suberoylanilide hydroxamic acid (SAHA) has been approved for the treatment of cutaneous T-cell lymphoma (CTCL), but its mode of action remained largely elusive. Vorinostat 33-37 TSPY like 2 Homo sapiens 105-109 22189940-1 2012 Several histone deacetylase inhibitors (HDACi), including vorinostat, have been approved for the therapy of cutaneous T-cell lymphoma (CTCL). Vorinostat 58-68 TSPY like 2 Homo sapiens 135-139 22416775-2 2012 Vorinostat, a pan-HDAC-I and, most recently, romidepsin, a bicyclic pan-HDAC-I, have been US FDA approved for treatment of relapsed or refractory CTCL. Vorinostat 0-10 TSPY like 2 Homo sapiens 146-150 22825908-1 2012 Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL). Vorinostat 0-10 TSPY like 2 Homo sapiens 131-135 22825908-3 2012 We describe the case of a 49 year-old male with a history of CTCL actively undergoing treatment with vorinostat. Vorinostat 101-111 TSPY like 2 Homo sapiens 61-65 20479100-1 2010 PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed. Vorinostat 139-149 TSPY like 2 Homo sapiens 197-201 21198545-4 2011 EXPERIMENTAL APPROACH: CTCL cell lines and primary CTCL cells were treated in vitro with vorinostat or romidepsin, or with STAT3 pathway inhibitors. Vorinostat 89-99 TSPY like 2 Homo sapiens 23-27 21132350-3 2010 Presently, two of these agents, vorinostat and romidepsin, have been approved in the US for the treatment of relapsed and refractory cutaneous T cell lymphomas (CTCL). Vorinostat 32-42 TSPY like 2 Homo sapiens 161-165 20127862-10 2010 Interestingly, panobinostat could induce cytotoxicity in vorinostat-resistant CTCL cells by downregulating phosphorylated STAT3 and STAT5 proteins. Vorinostat 57-67 TSPY like 2 Homo sapiens 78-82 21591544-2 2011 In particular, with recent FDA approvals of the three new agents vorinostat (Zolinza), romidepsin (Istodax), and pralatrexate (Folotyn) CTCL treatment has been transformed. Vorinostat 65-75 TSPY like 2 Homo sapiens 136-140 21879444-5 2011 Recently, the two HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, Vorinostat) and Romidepsin (Depsipeptide, FK228) were FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL). Vorinostat 34-65 TSPY like 2 Homo sapiens 188-192 21879444-5 2011 Recently, the two HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, Vorinostat) and Romidepsin (Depsipeptide, FK228) were FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL). Vorinostat 67-71 TSPY like 2 Homo sapiens 188-192 21110829-5 2011 Two of them, the hydroxamic acid (SAHA) and Romidepsin (FK 228), are approved in the second line treatment of refractory, persistent or relapsed Cutaneous T Cell Lymphoma (CTCL). Vorinostat 34-38 TSPY like 2 Homo sapiens 172-176 20479100-2 2010 SUMMARY: Vorinostat is a novel histone deacetylase (HDAC) inhibitor approved for the treatment of advanced CTCL. Vorinostat 9-19 TSPY like 2 Homo sapiens 107-111 20479100-7 2010 In two Phase II studies, patients with CTCL treated with oral vorinostat demonstrated significant reductions in skin lesions and decreased disease progression. Vorinostat 62-72 TSPY like 2 Homo sapiens 39-43 20479100-11 2010 CONCLUSION: Vorinostat, a novel HDAC inhibitor, is efficacious and well tolerated in patients with CTCL and is being investigated for its efficacy and safety in other types of cancers and as a part of combination therapy. Vorinostat 12-22 TSPY like 2 Homo sapiens 99-103 20132536-3 2010 One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Vorinostat 28-38 TSPY like 2 Homo sapiens 105-109 20371442-7 2010 This review aims to assess the clinical progress that vorinostat and other HDAC inhibitors have made in symptom relief and treatment of patients with CTCL and to provide practical advice for the management of associated toxicities. Vorinostat 54-64 TSPY like 2 Homo sapiens 150-154 19817748-1 2010 Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL). Vorinostat 0-10 TSPY like 2 Homo sapiens 148-152 19817748-1 2010 Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL). Vorinostat 12-43 TSPY like 2 Homo sapiens 148-152 19817748-1 2010 Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL). Vorinostat 45-49 TSPY like 2 Homo sapiens 148-152 19817748-1 2010 Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL). Vorinostat 51-58 TSPY like 2 Homo sapiens 148-152 18483262-1 2008 Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in approximately 30% of patients with advanced mycosis fungoides and Sezary syndrome cutaneous T-cell lymphoma (CTCL). Vorinostat 0-10 TSPY like 2 Homo sapiens 298-302 19951879-1 2009 INTRODUCTION: Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies. Vorinostat 14-24 TSPY like 2 Homo sapiens 218-222 19951879-9 2009 CONCLUSION: This post hoc subset analysis provides evidence for the long-term safety and clinical benefit of vorinostat in heavily pretreated patients with CTCL, regardless of previous treatment failures. Vorinostat 109-119 TSPY like 2 Homo sapiens 156-160 18665425-3 2008 METHODS: In a phase II trial of vorinostat for cutaneous T cell lymphoma (CTCL), 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET/computed tomography (CT) was performed on patients with both cutaneous and nodal disease. Vorinostat 32-42 TSPY like 2 Homo sapiens 74-78 19362413-4 2009 Clinical trials using these agents are now underway, with Vorinostat (suberoylanilide hydroxamic acid) having been approved by the FDA for treating cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease. Vorinostat 58-68 TSPY like 2 Homo sapiens 175-179 19362413-4 2009 Clinical trials using these agents are now underway, with Vorinostat (suberoylanilide hydroxamic acid) having been approved by the FDA for treating cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease. Vorinostat 70-101 TSPY like 2 Homo sapiens 175-179 18628067-7 2008 SAHA (vorinostat, Zolinza) was the first HDACi approved by the US Food and Drug Administration to enter the clinical oncology market for treating cutaneous T-cell lymphoma (CTCL) and is being tested for other malignancies. Vorinostat 0-4 TSPY like 2 Homo sapiens 173-177 18628067-7 2008 SAHA (vorinostat, Zolinza) was the first HDACi approved by the US Food and Drug Administration to enter the clinical oncology market for treating cutaneous T-cell lymphoma (CTCL) and is being tested for other malignancies. Vorinostat 6-16 TSPY like 2 Homo sapiens 173-177 18628067-7 2008 SAHA (vorinostat, Zolinza) was the first HDACi approved by the US Food and Drug Administration to enter the clinical oncology market for treating cutaneous T-cell lymphoma (CTCL) and is being tested for other malignancies. Vorinostat 18-25 TSPY like 2 Homo sapiens 173-177 18483262-2 2008 The purpose of this study was to identify biomarkers predictive of vorinostat response in CTCL using preclinical model systems and to assess these biomarkers in clinical samples. Vorinostat 67-77 TSPY like 2 Homo sapiens 90-94 18483262-7 2008 These results suggest that deregulation of STAT activity plays a role in vorinostat resistance in CTCL, and strategies that block this pathway may improve vorinostat response. Vorinostat 73-83 TSPY like 2 Homo sapiens 98-102 18483262-8 2008 Furthermore, these findings may be of prognostic value in predicting the response of CTCL patients to vorinostat. Vorinostat 102-112 TSPY like 2 Homo sapiens 85-89 17763605-5 2007 Vorinostat (suberoylanilide hydroxamic acid) is a histone deacetylases inhibitor that has recently been approved by the FDA for the treatment of progressive, persistent, or recurrent CTCL on or after 2 systemic therapies have failed. Vorinostat 0-10 TSPY like 2 Homo sapiens 183-187 19707308-0 2007 Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Vorinostat 70-80 TSPY like 2 Homo sapiens 54-58 19707308-2 2007 Vorinostat (Zolinza()) is the first FDA approved HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat 0-10 TSPY like 2 Homo sapiens 122-126 19707308-2 2007 Vorinostat (Zolinza()) is the first FDA approved HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat 12-19 TSPY like 2 Homo sapiens 122-126 19707308-4 2007 In two Phase II trials, vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 24%-30% in refractory advanced patients with CTCL including large cell transformation and Sezary syndrome (SS). Vorinostat 24-34 TSPY like 2 Homo sapiens 166-170 17940636-3 2007 Vorinostat (Zolinza, Merck & Co., Whitehouse Station, NJ, USA) is the first HDAC-I approved by the U.S. Food and Drug Administration for treatment of the cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat 0-10 TSPY like 2 Homo sapiens 227-231 17940636-5 2007 In two phase II trials, Vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 30-31% in refractory advanced patients with CTCL including large cell transformation and Sezary syndrome. Vorinostat 24-34 TSPY like 2 Homo sapiens 165-169 17594194-2 2007 Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Vorinostat 0-10 TSPY like 2 Homo sapiens 162-166 17594194-2 2007 Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Vorinostat 12-43 TSPY like 2 Homo sapiens 162-166 17594194-4 2007 In two Phase II trials, vorinostat 400 mg/day was safe and effective with an overall response rate of 24-30% in refractory advanced patients with CTCL including large cell transformation and Sezary syndrome. Vorinostat 24-34 TSPY like 2 Homo sapiens 146-150 17763605-5 2007 Vorinostat (suberoylanilide hydroxamic acid) is a histone deacetylases inhibitor that has recently been approved by the FDA for the treatment of progressive, persistent, or recurrent CTCL on or after 2 systemic therapies have failed. Vorinostat 12-43 TSPY like 2 Homo sapiens 183-187 17438089-4 2007 Vorinostat could be considered active in CTCL if observed response rate was at least 20% and the lower bound of the corresponding 95% confidence interval (95% CI) excluded 5%. Vorinostat 0-10 TSPY like 2 Homo sapiens 41-45 17438089-12 2007 CONCLUSIONS: Vorinostat showed activity in CTCL, and skin responses were a clinical benefit. Vorinostat 13-23 TSPY like 2 Homo sapiens 43-47 17438089-13 2007 Vorinostat was approved for treatment of cutaneous manifestations of CTCL. Vorinostat 0-10 TSPY like 2 Homo sapiens 69-73 16960145-0 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Vorinostat 22-32 TSPY like 2 Homo sapiens 115-119 16960145-12 2007 Vorinostat demonstrated activity in heavily pretreated patients with CTCL. Vorinostat 0-10 TSPY like 2 Homo sapiens 69-73 17109024-3 2007 Notably, the pleiotropic HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and depsipeptide, have shown efficacy in a wide range of cancers, in particular for cutaneous T-cell lymphoma (CTCL), and are progressing in phase II clinical studies. Vorinostat 42-73 TSPY like 2 Homo sapiens 192-196 17109024-3 2007 Notably, the pleiotropic HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and depsipeptide, have shown efficacy in a wide range of cancers, in particular for cutaneous T-cell lymphoma (CTCL), and are progressing in phase II clinical studies. Vorinostat 75-79 TSPY like 2 Homo sapiens 192-196 17286158-7 2006 Since the submission of this manuscript, vorinostat (Zolinza), an orally administered histone inhibitor, has been FDA approved for treating skin manifestations in patients with CTCL. Vorinostat 41-51 TSPY like 2 Homo sapiens 177-181 17286158-7 2006 Since the submission of this manuscript, vorinostat (Zolinza), an orally administered histone inhibitor, has been FDA approved for treating skin manifestations in patients with CTCL. Vorinostat 53-60 TSPY like 2 Homo sapiens 177-181 34765562-4 2021 Romidepsin and vorinostat are approved for CTCL treatment, while 5-azacytidine is approved for the treatment of several hematological disorders, but not for CTCL. Vorinostat 15-25 TSPY like 2 Homo sapiens 43-47 27935859-2 2017 Because the histone deacetylase inhibitor (HDACI) vorinostat showed excellent outcomes for treating advanced CTCL, HDACIs may reduce the metastasis of CTCL by targeting miR-150 and/ or CCR6. Vorinostat 50-60 TSPY like 2 Homo sapiens 109-113 28537899-5 2017 When combining Sorafenib with the established CTCL medication Vorinostat we detected an increase in cell death sensitivity in CTCL cells. Vorinostat 62-72 TSPY like 2 Homo sapiens 46-50 28537899-5 2017 When combining Sorafenib with the established CTCL medication Vorinostat we detected an increase in cell death sensitivity in CTCL cells. Vorinostat 62-72 TSPY like 2 Homo sapiens 126-130 28537899-8 2017 Taken together, these findings suggest that Sorafenib in combination with Vorinostat represents a novel therapeutic approach for the treatment of CTCL patients. Vorinostat 74-84 TSPY like 2 Homo sapiens 146-150 27935859-2 2017 Because the histone deacetylase inhibitor (HDACI) vorinostat showed excellent outcomes for treating advanced CTCL, HDACIs may reduce the metastasis of CTCL by targeting miR-150 and/ or CCR6. Vorinostat 50-60 TSPY like 2 Homo sapiens 151-155 27935859-4 2017 We found that pan- HDACIs (vorinostat and panobinostat) inhibited the migration of CTCL cells and downregulated CCR6. Vorinostat 27-37 TSPY like 2 Homo sapiens 83-87 26640145-10 2016 Furthermore, we found that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restored the expression of miR-16 and its essential targets, induced senescence in CTCL cells expressing wild-type p53 and promoted apoptosis in cells with nonfunctional p53. Vorinostat 61-92 TSPY like 2 Homo sapiens 183-187 26640145-10 2016 Furthermore, we found that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restored the expression of miR-16 and its essential targets, induced senescence in CTCL cells expressing wild-type p53 and promoted apoptosis in cells with nonfunctional p53. Vorinostat 94-98 TSPY like 2 Homo sapiens 183-187 26640145-13 2016 Elucidation of the essential targets of miR-16 and SAHA provides a basis for the clinical application of SAHA in the treatment of CTCL and other non-Hodgkin T/NK-cell lymphomas. Vorinostat 51-55 TSPY like 2 Homo sapiens 130-134 26640145-13 2016 Elucidation of the essential targets of miR-16 and SAHA provides a basis for the clinical application of SAHA in the treatment of CTCL and other non-Hodgkin T/NK-cell lymphomas. Vorinostat 105-109 TSPY like 2 Homo sapiens 130-134 26811014-4 2016 Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Vorinostat 165-175 TSPY like 2 Homo sapiens 68-72 26848526-2 2016 Suberoylanilide hydroxamic acid (SAHA), the first HDI approved for the treatment of cutaneous T cell lymphoma (CTCL), is currently being tested in clinical trials for other cancers. Vorinostat 0-31 TSPY like 2 Homo sapiens 111-115 26848526-2 2016 Suberoylanilide hydroxamic acid (SAHA), the first HDI approved for the treatment of cutaneous T cell lymphoma (CTCL), is currently being tested in clinical trials for other cancers. Vorinostat 33-37 TSPY like 2 Homo sapiens 111-115 24806744-1 2015 Since the approval of vorinostat for the treatment of refractory cutaneous epidermotropic T-cell lymphoma (CTCL) in 2006, very little data about this treatment have been published. Vorinostat 22-32 TSPY like 2 Homo sapiens 107-111 24806744-2 2015 The aim of this retrospective study was to assess the efficacy and safety of vorinostat in patients with CTCL treated between 2007 and 2013 in our department. Vorinostat 77-87 TSPY like 2 Homo sapiens 105-109 24806744-9 2015 Vorinostat could be a therapeutic alternative for CTCL after treatment failure. Vorinostat 0-10 TSPY like 2 Homo sapiens 50-54